Ariad Pharmaceuticals Price Target Lowered to $7.00 at Jefferies Group (ARIA)
Equities research analysts at Jefferies Group cut their target price on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $23.00 to $7.00 in a research note issued to investors on Wednesday, AnalystRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price indicates a potential upside of 20.07% from the stock’s previous close.
Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) traded down 65.99% on Wednesday, hitting $5.83. 114,909,144 shares of the company’s stock traded hands. Ariad Pharmaceuticals has a 1-year low of $4.00 and a 1-year high of $25.40. The stock has a 50-day moving average of $19.16 and a 200-day moving average of $18.46. The company’s market cap is $1.079 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) last released its earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.40) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter last year, the company posted ($0.31) earnings per share. Ariad Pharmaceuticals’s revenue was up 4302.5% compared to the same quarter last year. On average, analysts predict that Ariad Pharmaceuticals will post $-1.63 earnings per share for the current fiscal year.
ARIA has been the subject of a number of other recent research reports. Analysts at Cowen and Company cut their price target on shares of Ariad Pharmaceuticals from $27.50 to $10.00 in a research note to investors on Wednesday. Separately, analysts at BMO Capital Markets cut their price target on shares of Ariad Pharmaceuticals from $21.00 to $8.00 in a research note to investors on Wednesday. They now have a “market perform” rating on the stock. Finally, analysts at Maxim Group downgraded shares of Ariad Pharmaceuticals from a “buy” rating to a “hold” rating in a research note to investors on Wednesday. They now have a $24.00 price target on the stock. Seven analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Ariad Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $22.75.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.